Observational studyFrontiers in immunology2026
Effect of lymph node dissection numbers after conversion immunochemotherapy on the survival of gastric cancer patients: a multi-center retrospective study.
Observational study in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the influence of lymph node dissection on the prognosis of unresectable locally advanced gastric cancer (LAGC) after conversion immunochemotherapy (CICT). Methods: A total of 287 patients, including 227 from Nanjing Drum Tower Hospital and an external validation cohort of 60 patients (15 from Peking Union Medical College Hospital, 20 from Beijing Friendship Hospital, and 25 from PLA General Hospital) with pathologically diagnosed unresectable primary LAGC (cT3~4N+) underwent radical gastrectomy after multidisciplinary evaluation conversion immunochemotherapy (CICT) were enrolled, and their clinical data were collected. According to the pathological data of patients' baseline data set, a clinical prediction model of patients' overall survival (OS) and progression-free survival (PFS) was established, and based on COX regression model, the critical value of the number of lymph node dissection was determined by restricted cubic spline (RCS) analysis. Results: Univariate and multivariate COX regression analysis showed that lymph node metastasis (ypN+) was an independent risk factor for OS (P = 0.030) and PFS (P = 0.002). According to the results of COX regression analysis, the prediction model was established. RCS curve showed that the critical number of lymph node dissection was 21 and 28. Patients with 21-28 lymph node dissection had the best OS and PFS. Compared with the patients with 21-28 lymph nodes dissection, the patients with less than 21 lymph nodes dissection had worse OS (P<0.001) and PFS (P = 0.002). Those with more than 28 lymph nodes isolated had worse OS(P = 0.043) and PFS (P = 0.027). The PFS of patients with more than 28 lymph nodes dissection was better than the patients with less than 21lymph nodes dissection (P = 0.031). Although the difference was not statistically significant, the total OS of patients with more than 28 lymph nodes dissection was still higher than that of patients with less than 21 lymph nodes dissection (P = 0.077). Conclusion: Among patients after CICT, lymph node metastasis (ypN+) is an independent risk factor for the prognosis of patients. The survival benefit of patients with less than 21 lymph node dissection is significantly reduced, while those with more than 28 lymph node dissection are less than 21-28 lymph node dissection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.